Innovating Clinical Trials
Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.
Ted Trafford - https://probitymedical.com/
With almost 30 years of experience in clinical research, Ted serves as the Director of Business Development, driving business growth and leading Feasibility and Site Relationship teams at Probity Medical Research, a clinical trial site administrative support company with a consortium of 70+ sites across four countries. As a writer and speaker, Ted contributes to thought leadership and strategic initiatives in the clinical trials industry, leveraging his extensive experience and creative approach to drive meaningful discussion and progress for Sponsors, CROs, Sites and Technology Vendors.
Liam Eves - https://www.theendpointpodcast.com/
Liam's held executive roles in SMOs and CROs, and led all major functions of trial delivery. His journey into the field began unexpectedly after an injury ended his career as a professional footballer. Over the years Liam has optimized trial delivery methods / systems for effective enrollment and trial delivery. Currently, he focuses on building and advising companies in the clinical trial space.
Innovating Clinical Trials
ICT Ep27: Expanding the Scope of Feasibility in Clinical Trials with Nick Palumbo (Part 3 of 3)
Welcome to the Innovating Clinical Trials podcast, where we explore the evolving landscape of clinical research. In this episode, hosts Liam Eves and Ted Trafford continue the conversation with clinical trial feasibility expert Nick Palumbo to examine why feasibility is much more than just site selection—and how rethinking the process can drive better enrollment and study success.
Nick shares his insights on the broader role of feasibility, from protocol optimization to enrollment modeling, and the critical need for strong relationships with both internal and external stakeholders. He also highlights why personalized site engagement—not mass emails—is essential to fostering collaboration and improving trial outcomes.
This episode takes a candid look at persistent industry challenges, including the long-standing failure of 80% of studies to meet enrollment goals, and explores how re-evaluating feasibility practices could be a key part of the solution. If you want to understand how feasibility can be leveraged as a strategic advantage in clinical trials, this discussion is for you.